Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01816971 · FLOW

Participant flow

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2026-04-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    INDUCTION THERAPY: Patients receive dexamethasone IV or PO QD on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.. TRANSPLANT: Patients undergo autologous stem cell transplant. CONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in induction. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days for 10 courses in the absence of disease progression or unacceptable toxicity. dexamethasone: Given IV or PO carfilzomib: Given IV lenalidomide: Given PO autologous hematopoietic stem cell transplantation: Undergo autologous hematopoietic stem cell transplant laboratory biomarker analysis: Correlative studies
    id
    FG000
    title
    Treatment (Dexamethasone, Carfilzomib, Lenalidomide)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        76
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        64
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        12
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    INDUCTION THERAPY: Patients receive dexamethasone IV or PO QD on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.. TRANSPLANT: Patients undergo autologous stem cell transplant. CONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in induction. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days for 10 courses in the absence of disease progression or unacceptable toxicity. dexamethasone: Given IV or PO carfilzomib: Given IV lenalidomide: Given PO autologous hematopoietic stem cell transplantation: Undergo autologous hematopoietic stem cell transplant laboratory biomarker analysis: Correlative studies
    id
    FG000
    title
    Treatment (Dexamethasone, Carfilzomib, Lenalidomide)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        76
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        64
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        12
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice